DocMorris AG/€DOCM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About DocMorris AG
DocMorris AG operates in the healthcare industry, focusing on providing pharmaceutical services as a leading online pharmacy in Europe. The company offers a wide range of prescription and over-the-counter medications, healthcare products, and services through its e-commerce platform. Founded in 2000, DocMorris is headquartered in Heerlen, the Netherlands. It holds a unique strategic position by leveraging digital technology to enhance customer convenience and streamline the medication procurement process. The company’s core strength lies in its extensive network and efficient delivery system, catering to a broad customer base across multiple European countries.
Ticker
€DOCM
Sector
Primary listing
XGAT
Employees
1,454
Headquarters
Frauenfeld, Switzerland
Website
DocMorris AG Metrics
BasicAdvanced
€318M
-
-€6.35
1.50
-
Price and volume
Market cap
€318M
Beta
1.5
52-week high
€42.40
52-week low
€6.06
Average daily volume
15K
Financial strength
Current ratio
3.251
Quick ratio
2.853
Long term debt to equity
63.775
Total debt to equity
64.652
Interest coverage (TTM)
-4.04%
Profitability
EBITDA (TTM)
-105.108
Gross margin (TTM)
21.68%
Net profit margin (TTM)
-11.38%
Operating margin (TTM)
-10.57%
Effective tax rate (TTM)
3.54%
Revenue per employee (TTM)
€785,180
Management effectiveness
Return on assets (TTM)
-7.70%
Return on equity (TTM)
-27.47%
Valuation
Price to revenue (TTM)
0.119
Price to book
0.59
Price to tangible book (TTM)
-41.49
Price to free cash flow (TTM)
-1.273
Free cash flow yield (TTM)
-78.55%
Free cash flow per share (TTM)
-5.208
Growth
Revenue change (TTM)
5.93%
Earnings per share change (TTM)
-28.87%
3-year revenue growth (CAGR)
-8.38%
10-year revenue growth (CAGR)
1.96%
3-year earnings per share growth (CAGR)
-36.81%
Bulls say / Bears say
External revenue rose 10.2% YoY to CHF 572.1 million in H1 2025, led by a 7.1% increase in Q2, showing strong top-line momentum in core markets (PharmiWeb)
Prescription (Rx) revenue jumped 43.5% YoY in H1 2025, buoyed by Germany’s e-prescription rollout and digital platform upgrades (FinanzWire)
DocMorris completed a CHF 200 million capital increase in Q1 2025 with a 99% take-up rate, bolstering the balance sheet to support medium-term growth objectives (FinanzWire)
Adjusted EBITDA remained negative at CHF 28.8 million in H1 2025 despite revenue growth, highlighting continued unprofitability in the core business (PharmiWeb)
Guidance for Q1 2025 forecasts an adjusted EBITDA loss of CHF 35–55 million, including about CHF 15 million in additional Rx marketing expenses, indicating ongoing cash outflow and pressure on free cash flow (PharmiWeb)
Non-Rx revenue grew by just 4.4% YoY in H1 2025, pointing to limited diversification beyond the prescription segment and dependence on Rx growth (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DocMorris AG stock?
DocMorris AG (DOCM) has a market cap of €318M as of October 15, 2025.
What is the P/E ratio for DocMorris AG stock?
The price to earnings (P/E) ratio for DocMorris AG (DOCM) stock is 0 as of October 15, 2025.
Does DocMorris AG stock pay dividends?
No, DocMorris AG (DOCM) stock does not pay dividends to its shareholders as of October 15, 2025.
When is the next DocMorris AG dividend payment date?
DocMorris AG (DOCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DocMorris AG?
DocMorris AG (DOCM) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.